0001213900-21-044669.txt : 20210825 0001213900-21-044669.hdr.sgml : 20210825 20210825061113 ACCESSION NUMBER: 0001213900-21-044669 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210824 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210825 DATE AS OF CHANGE: 20210825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alpha Healthcare Acquisition Corp. CENTRAL INDEX KEY: 0001818382 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851763759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39532 FILM NUMBER: 211203550 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10105 BUSINESS PHONE: 6463213444 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10105 8-K 1 ea146398-8k_alphahealth.htm CURRENT REPORT
0001818382 false 0001818382 2021-08-24 2021-08-24 0001818382 AHAC:UnitsEachConsistingOfOneShareOfClassaCommonStockAndOnehalfOfOneRedeemableWarrantMember 2021-08-24 2021-08-24 0001818382 AHAC:ClassCommonStockParValue0.0001PerShareMember 2021-08-24 2021-08-24 0001818382 AHAC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50Member 2021-08-24 2021-08-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 24, 2021

 

ALPHA HEALTHCARE ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Delaware

  

001-39532

  

85-1763759

(State or other jurisdiction
of incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

1177 Avenue of the Americas, 5th Floor

New York, New York

  

10036

(Address of principal executive offices)   (Zip Code)

 

(646) 494-3296

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbols

  

Name of each exchange on which registered

Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant   AHACU   The Nasdaq Stock  Market LLC
Class A Common Stock, par value $0.0001 per share   AHAC   The Nasdaq Stock  Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50   AHACW   The Nasdaq Stock  Market LLC

 

☒Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders

 

On August 24, 2021, Alpha Healthcare Acquisition Corp., a Delaware corporation (“AHAC” or the “Company”), held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, a total of least 7,912,056 shares (61.55%) of AHAC’s issued and outstanding common stock held of record as of July 21, 2021, the record date for the Special Meeting, were present either in person or by proxy, which constituted a quorum. Of these 7,912,056 shares of common stock, 2,500,000 were Class B Common Stock, par value $0.0001 per share, of AHAC (“Class B Common Stock”) and 5,412,056 were Class A Common Stock, par value $0.0001 per share, of AHAC (“Class A Common Stock”). AHAC’s stockholders voted on the following proposals at the Special Meeting, which were set forth in the definitive proxy statement/prospectus for the Special Meeting that was filed with the Securities and Exchange Commission (the “SEC”) on August 4, 2021 (the “Final Prospectus”), each of which was approved. The final vote tabulation for each proposal is set forth below.

 

1.The Business Combination Proposal. To adopt a proposal to (a) adopt and approve the Business Combination Agreement, dated as of February 17, 2021 (the “Business Combination Agreement”), by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation (“Merger Sub”), a wholly-owned subsidiary of AHAC, and Humacyte, Inc., a Delaware corporation (“Humacyte”), pursuant to which Merger Sub will merge with and into Humacyte, with Humacyte surviving the merger as a wholly-owned subsidiary of AHAC and (b) approve the Business Combination (as defined in the Business Combination Agreement). In connection with the Business Combination, AHAC will be renamed “Humacyte, Inc.” (“New Humacyte”) and Humacyte will be renamed “Humacyte Global, Inc.” Subject to the terms and conditions set forth in the Business Combination Agreement, at the Effective Time (as defined in the Business Combination Agreement):

 

i.each share of common stock of Humacyte (“Humacyte Common Stock”) outstanding as of immediately prior to the Effective Time will be cancelled and converted into the right to receive a number of shares of common stock, $0.0001 par value per share, of New Humacyte (“New Humacyte Common Stock”), based on an exchange ratio based on an implied Humacyte vested equity value of $800,000,000 (the “Exchange Ratio”);

 

ii.each share of preferred stock of Humacyte (“Humacyte Preferred Stock”) outstanding as of immediately prior to the Effective Time will be cancelled and converted into the right to receive a number of shares of New Humacyte Common Stock based on the aggregate number of shares of Humacyte Common Stock that would be issued upon conversion of the shares of Humacyte Preferred Stock based on the applicable conversion ratio immediately prior to the Effective Time, multiplied by the Exchange Ratio;

 

iii.each outstanding option or warrant to purchase Humacyte Common Stock will be converted into an option or warrant, as applicable, to purchase a number of shares of New Humacyte Common Stock equal to (i) the number of shares of Humacyte Common Stock subject to such option or warrant multiplied by (ii) the Exchange Ratio at an exercise price per share equal to (iii) the exercise price per share for such option or warrant immediately prior to the Effective Time divided by (iv) the Exchange Ratio; and

 

iv.each share of Class A Common Stock and each share of Class B Common Stock that is issued and outstanding immediately prior to the Effective Time shall become one share of New Humacyte Common Stock:

 

Votes For   Votes Against   Abstentions

7,862,833

  

42,414

  

6,809

 

2.The Charter Amendment Proposal. To adopt a proposal to approve a proposed amended and restated certificate of incorporation (the “Proposed Charter”), which will amend and restate AHAC’s current certificate of incorporation (the “Current Charter”), and which Proposed Charter will be in effect upon the Closing (as defined in the Business Combination Agreement):

 

Votes For   Votes Against   Abstentions
5,356,362 (Class A Common Stock)   40,596 (Class A Common Stock)   15,098 (Class A Common Stock)
2,500,000 (Class B Common Stock)   0 (Class B Common Stock)   0 (Class B Common Stock)

 

3.The Advisory Charter Amendment Proposals. To adopt proposals to approve, on a non-binding advisory basis, the following material differences between the Proposed Charter and the Current Charter, which are being presented in accordance with the requirements of the SEC as eight separate sub-proposals:

 

(a)Advisory Charter Proposal A – To change the corporate name of New Humacyte to “Humacyte, Inc.”:

 

Votes For   Votes Against   Abstentions

7,807,941

  

75,894

  

28,221

 

1

 

 

(b)Advisory Charter Proposal B – To increase the authorized shares of common stock of AHAC to 250,000,000 shares:

 

Votes For   Votes Against   Abstentions

7,595,106

  

258,051

  

58,899

 

(c)Advisory Charter Proposal C – To increase the authorized shares of “blank check” preferred stock that New Humacyte’s board of directors could issue to 20,000,000 shares:

 

Votes For   Votes Against   Abstentions

7,529,679

  

313,746

  

68,631

 

(d)Advisory Charter Proposal D – To provide that the removal of any director be only for cause and that the affirmative vote of at least 66 2/3% of New Humacyte’s then-outstanding shares of capital stock entitled to vote generally in the election of directors:

 

Votes For   Votes Against   Abstentions

7,660,343

  

207,230

  

44,483

 

(e)Advisory Charter Proposal E – To provide that certain amendments to provisions of the Proposed Charter will require the approval of at least 66 2/3% of New Humacyte’s then-outstanding shares of capital stock entitled to vote on such amendment:

 

Votes For   Votes Against   Abstentions

7,698,602

  

165,914

  

47,540

 

(f)Advisory Charter Proposal F – To make New Humacyte’s corporate existence perpetual as opposed to AHAC’s corporate existence, which is required to be dissolved and liquidated 24 months following the closing of its initial public offering, and remove from the Proposed Charter the various provisions applicable only to special purpose acquisition companies:

 

Votes For   Votes Against   Abstentions

7,800,856

  

87,537

  

23,663

 

(g)Advisory Charter Proposal G – To provide that certain amendments to provisions of the Proposed Charter will remove the provision that allows stockholders to act by written consent as opposed to holding a stockholders’ meeting:

 

Votes For   Votes Against   Abstentions

7,648,907

  

217,317

  

45,832

 

4.The Nasdaq Stock Issuance Proposal. To adopt a proposal to approve (a) the issuance of up to 95,000,000 newly issued shares of New Humacyte Common Stock in the Business Combination, which amount will be determined as described as described in the Final Prospectus, and (b) the issuance of an aggregate of 17,500,000 shares of New Humacyte Common Stock in the PIPE Investment (as defined in the Business Combination Agreement):

 

Votes For   Votes Against   Abstentions

7,791,609

  

95,537

  

24,910

 

2

 

 

5.The Director Election Proposal. To approve the appointment of 11 directors who, upon consummation of the Business Combination, will become directors of New Humacyte:

 

Director Nominee  Votes For   Votes Withheld 
Brady Dougan  7,790,780   121,276 
Jeffrey H. Lawson, M.D., Ph.D.  7,791,688   120,368 
Max Wallace, J.D.  7,789,883   122,173 
Gordan M. Binder  7,790,250   121,806 
Todd M. Pope  7,788,646   123,410 
Kathleen Sebelius  7,748,962   163,094 
Rajiv Shukla  7,788,132   123,924 
Emery N. Brown, M.D., Ph.D.  7,792,610   119,446 
Michael T. Constantino  7,789,146   122,910 
Laura E. Niklason, M.D., Ph.D.  7,793,030   119,026 
Susan Windham-Bannister, Ph.D.  7,792,426   119,630 

 

6.The Incentive Plan Proposal. To adopt a proposal to approve the Humacyte, Inc. 2021 Long-Term Incentive Plan, a copy of which is appended the Final Prospectus as Annex D, which will become effective as of the Closing:

 

Votes For   Votes Against   Abstentions
7,733,093   125,796   53,167

 

  7. The Employee Stock Purchase Plan Proposal. To adopt a proposal to approve the Humacyte, Inc. 2021 Employee Stock Purchase Plan, a copy of which is appended to the Final Prospectus as Annex E, which will become effective as of the Closing; and

 

Votes For   Votes Against   Abstentions
7,726,909   147,650   37,497

 

  8. The Adjournment Proposal. To adopt a proposal to adjourn the Special Meeting to a later date or dates if it is determined that more time is necessary to approve, in the judgement of the board of directors of AHAC or the officer presiding over the Special Meeting, for AHAC to consummate the Business Combination.

 

Votes For   Votes Against   Abstentions
7,782,864   95,212   33,980

 

Item 8.01 Other Events

 

On August 24, 2021, AHAC and Humacyte issued a press release announcing that AHAC’s stockholders approved the Business Combination and the other proposals presented at the Special Meeting. This press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and incorporated into this Item 8.01 by reference.  

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

Number

   Description
99.1   Press Release, dated August 24, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

[Signature Page Follows]

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf by the undersigned hereunto duly authorized.

 

Date: August 24, 2021 ALPHA HEALTHCARE ACQUISITION CORP.
   
  By:   /s/ Rajiv Shukla
    Rajiv Shukla
    Chief Executive Officer

 

 

4

 

 

 

 

 EX-99.1 2 ea146398ex99-1_alphahealth.htm PRESS RELEASE, DATED AUGUST 24, 2021

Exhibit 99.1

 

A blue and white logo Description automatically generated with medium confidence

 

 Alpha Healthcare Acquisition Corp. Announces Shareholder Approval

of Business Combination with Humacyte

 

NEW YORK and Durham, N.C. – August 24, 2021 – Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, and all other proposals presented at AHAC’s special shareholder’s meeting held on August 24, 2021.

 

AHAC Shareholders approved the Business Combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC votes cast at the meeting. AHAC plans to file the results of the meeting, as tabulated by an independent inspector of elections, on a Form 8-K with the Securities and Exchange Commission (the “SEC”).

 

Subject to the satisfaction or waiver of the other customary closing conditions, the business combination is expected to close on August 26, 2021. Following the closing, the combined company will operate as Humacyte, Inc. and on or about August 27, 2021, its shares of common stock and warrants are expected to begin trading on the Nasdaq Global Select Market® under the new ticker symbols “HUMA” and “HUMAW,” respectively.

 

About Humacyte

 

Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

 

About Alpha Healthcare Acquisition Corp.

 

Alpha Healthcare Acquisition Corp. (ticker: AHAC) is a special purpose acquisition company formed for the purpose of effecting a business combination with one or more businesses in the healthcare sector. The company was founded by Mr. Rajiv Shukla who has two decades of buyouts, investments and operations experience in the healthcare industry. Mr. Shukla previously served as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp., a Nasdaq-listed special purpose acquisition company, that merged with DermTech, Inc (ticker: DMTK) in August 2019. On February 17, 2021, AHAC announced a definitive agreement to merge with Humacyte, Inc. along with a concurrent fully committed PIPE placement of $175 million of AHAC common shares at a price of $10.00 per share.

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing, progress, and results of our clinical trials; the anticipated characteristics and performance of our HAVs, our ability to successfully complete, clinical trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the commercialization of our HAVs and our ability to manufacture at commercial scale; the implementation of our business model, strategic plans for our business; the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology; the timing or likelihood of regulatory filings and approvals; timing, scope, and rate of reimbursement for our HAVs; our estimated available market opportunity; the proposed business combination, including the timing and structure of the business combination, the proceeds of the business combination, and the benefits of the business combination. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the ability to complete the business combination due to the failure to obtain approval from AHAC’s shareholders or satisfy other closing conditions in the Business Combination Agreement, the occurrence of any event that could give rise to the termination of the Business Combination Agreement, the ability to recognize the anticipated benefits of the business combination, the outcome of any legal proceedings that may be instituted against AHAC or Humacyte following announcement of the proposed business combination and related transactions, the impact of COVID-19 on Humacyte’s business and/or the ability of the parties to complete the business combination, the ability to obtain or maintain the listing AHAC’s common stock on Nasdaq following the proposed business combination, costs related to the proposed business combination, changes in applicable laws or regulations, the possibility that AHAC or Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those included under the header “Risk Factors” in the registration statement on Form S-4 filed by AHAC with the SEC and those included under the header “Risk Factors” in the final prospectus of AHAC related to its initial public offering. Most of these factors are outside of AHAC’s and Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

  

###

 

Humacyte Investor Contact:

investors@humacyte.com

 

Humacyte Media Contact:

media@humacyte.com

 

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 4 image_002.jpg GRAPHIC begin 644 image_002.jpg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end EX-101.DEF 5 ahac-20210824_def.xml XBRL DEFINITION FILE EX-101.LAB 6 ahac-20210824_lab.xml XBRL LABEL FILE Class of Stock [Axis] Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant Class A Common Stock, par value $0.0001 per share Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 Statement [Table] Affiliate, Collateralized Security [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 ahac-20210824_pre.xml XBRL PRESENTATION FILE EX-101.SCH 8 ahac-20210824.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 9 ea146398-8k_alphahealth_htm.xml IDEA: XBRL DOCUMENT 0001818382 2021-08-24 2021-08-24 0001818382 AHAC:UnitsEachConsistingOfOneShareOfClassaCommonStockAndOnehalfOfOneRedeemableWarrantMember 2021-08-24 2021-08-24 0001818382 AHAC:ClassCommonStockParValue0.0001PerShareMember 2021-08-24 2021-08-24 0001818382 AHAC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50Member 2021-08-24 2021-08-24 iso4217:USD shares iso4217:USD shares 0001818382 false 8-K 2021-08-24 ALPHA HEALTHCARE ACQUISITION CORP. DE 001-39532 85-1763759 1177 Avenue of the Americas  5th Floor New York NY 10036 (646) 494-3296 false false false false Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant AHACU NASDAQ Class A Common Stock, par value $0.0001 per share AHAC NASDAQ Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 AHACW NASDAQ true false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 24, 2021
Affiliate, Collateralized Security [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 24, 2021
Entity File Number 001-39532
Entity Registrant Name ALPHA HEALTHCARE ACQUISITION CORP.
Entity Central Index Key 0001818382
Entity Tax Identification Number 85-1763759
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1177 Avenue of the Americas
Entity Address, Address Line Two  5th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10036
City Area Code (646)
Local Phone Number 494-3296
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant  
Affiliate, Collateralized Security [Line Items]  
Title of 12(b) Security Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant
Trading Symbol AHACU
Security Exchange Name NASDAQ
Class A Common Stock, par value $0.0001 per share  
Affiliate, Collateralized Security [Line Items]  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol AHAC
Security Exchange Name NASDAQ
Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50  
Affiliate, Collateralized Security [Line Items]  
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
Trading Symbol AHACW
Security Exchange Name NASDAQ
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 4 96 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://alphahealthcareacq.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea146398-8k_alphahealth.htm ahac-20210824.xsd ahac-20210824_def.xml ahac-20210824_lab.xml ahac-20210824_pre.xml ea146398ex99-1_alphahealth.htm http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea146398-8k_alphahealth.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "ahac-20210824_def.xml" ] }, "inline": { "local": [ "ea146398-8k_alphahealth.htm" ] }, "labelLink": { "local": [ "ahac-20210824_lab.xml" ] }, "presentationLink": { "local": [ "ahac-20210824_pre.xml" ] }, "schema": { "local": [ "ahac-20210824.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 3, "memberStandard": 0, "nsprefix": "AHAC", "nsuri": "http://alphahealthcareacq.com/20210824", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea146398-8k_alphahealth.htm", "contextRef": "From2021-08-24to2021-08-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://alphahealthcareacq.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea146398-8k_alphahealth.htm", "contextRef": "From2021-08-24to2021-08-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "AHAC_ClassCommonStockParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Common Stock, par value $0.0001 per share" } } }, "localname": "ClassCommonStockParValue0.0001PerShareMember", "nsuri": "http://alphahealthcareacq.com/20210824", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "domainItemType" }, "AHAC_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50" } } }, "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50Member", "nsuri": "http://alphahealthcareacq.com/20210824", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "domainItemType" }, "AHAC_UnitsEachConsistingOfOneShareOfClassaCommonStockAndOnehalfOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units, each consisting of one share of Class\u00a0A Common Stock and one-half of one Redeemable Warrant" } } }, "localname": "UnitsEachConsistingOfOneShareOfClassaCommonStockAndOnehalfOfOneRedeemableWarrantMember", "nsuri": "http://alphahealthcareacq.com/20210824", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_AffiliateCollateralizedSecurityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Affiliate, Collateralized Security [Line Items]" } } }, "localname": "AffiliateCollateralizedSecurityLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://alphahealthcareacq.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001213900-21-044669-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-044669-xbrl.zip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end